Brind.

Amphastar Pharmaceuticals appointed Jack Zhang as President and CEO on August 13, 2025, and simultaneously secured an exclusive licensing agreement for peptide development commercialization in Canada.

3 reports, 2 independent Updated Aug 13
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
2
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Amphastar Pharmaceuticals appointed Jack Zhang as President and CEO on August 13, 2025, and simultaneously secured an exclusive licensing agreement for peptide development commercialization in Canada.

Who's involved

What this event is mainly about
Amphastar PharmaceuticalsJack Zhang

How it developed

Newest first. Tap a step to see who reported it.
  1. Amphastar appoints CEO Jack Zhang and secures exclusive licensing deal for peptide commercialization in Canada.1 source
  2. Amphastar plans to quadruple manufacturing capacity in Rancho Cucamonga following Jack Zhang's CEO appointment.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Pharmaceutical TechnologyAmphastar and Anji make licence agreement for three new peptides Amphastar Pharmaceuticals has signed an exclusive licence agreement with Nanjing Anji Biotechnology, focusing on the development, prod
  • ACCESS NewswireAmphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. Agreement strengthens proprietary peptide pipeline targeting hi
  • ACCESS NewswireAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 - Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025 - GAAP net income of $31